DJE Kapital AG Buys Shares of 257,897 Eli Lilly and Company $LLY

Key Points

• DJE Kapital AG opened a new position in Eli Lilly during the first quarter, buying 257,897 shares valued at about $234.5 million. The stake represents roughly 5.2% of the fund’s portfolio, making LLY its fourth-largest holding.
• Eli Lilly reported a strong quarter, with EPS of $8.55 and revenue of $19.8 billion, both beating analyst expectations. Revenue rose 55.5% year over year, and the company lifted its FY 2026 guidance to $35.50–$37.00 EPS.
• Despite a recent 2.7% stock drop, analyst sentiment remains constructive, with multiple firms raising price targets and the consensus rating at Moderate Buy. The stock is still widely held by institutions, which own about 82.5% of shares.

DJE Kapital AG bought a new position in Eli Lilly and Company (NYSE:LLY - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 257,897 shares of the company's stock, valued at approximately $234,543,000. Eli Lilly and Company makes up about 5.2% of DJE Kapital AG's portfolio, making the stock its 4th largest holding.

Several other hedge funds also recently modified their holdings of the business. Andra AP fonden raised its stake in shares of Eli Lilly and Company by 52.9% in the 1st quarter. Andra AP fonden now owns 127,233 shares of the company's stock valued at $117,025,000 after acquiring an additional 44,003 shares in the last quarter. Wilkerson Advisory Group LLC lifted its holdings in Eli Lilly and Company by 18.9% in the 1st quarter. Wilkerson Advisory Group LLC now owns 1,454 shares of the company's stock worth $1,337,000 after purchasing an additional 231 shares during the last quarter. Resolute Advisors LLC bought a new stake in Eli Lilly and Company during the first quarter worth approximately $351,000. Puzo Michael J boosted its position in Eli Lilly and Company by 7.2% during the first quarter. Puzo Michael J now owns 8,816 shares of the company's stock worth $8,109,000 after purchasing an additional 592 shares during the period. Finally, Rice Partnership LLC grew its holdings in Eli Lilly and Company by 3.5% during the first quarter. Rice Partnership LLC now owns 20,667 shares of the company's stock valued at $19,009,000 after purchasing an additional 701 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Down 2.7%

LLY opened at $1,146.90 on Tuesday. The business has a 50 day moving average of $1,122.49 and a 200-day moving average of $1,036.98. The stock has a market capitalization of $1.08 trillion, a price-to-earnings ratio of 40.74, a P/E/G ratio of 1.48 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same period in the prior year, the company earned $3.34 EPS. The business's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 24.58%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wolfe Research restated an "outperform" rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Weiss Ratings upgraded shares of Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday, July 1st. Royal Bank Of Canada lifted their target price on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an "outperform" rating in a report on Wednesday, July 8th. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research report on Tuesday, June 9th. Finally, Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a "hold" rating in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,283.64.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Investor interest remains strong in Eli Lilly thanks to its leadership in the fast-growing weight-loss and GLP-1 drug market, which continues to support long-term growth expectations.
• Positive Sentiment: Articles highlighting a possible stock split suggest shares trading above $1,000 could make LLY more accessible to retail investors and keep demand elevated.
• Positive Sentiment: Erste Group Bank issued an optimistic earnings estimate for LLY, reinforcing confidence in the company’s strong profit outlook.
• Neutral Sentiment: Coverage describing Eli Lilly as a trending stock shows the name remains heavily watched, which can amplify moves but does not by itself change fundamentals.
• Neutral Sentiment: Several valuation-focused articles argue the stock looks expensive or fully valued after its massive multi-year rally, suggesting expectations are already high.
• Neutral Sentiment: News about Eli Lilly’s $3.8 billion psychedelic-medicine deal and commentary around the ATAI buyout are more about strategic expansion than immediate revenue impact.
• Negative Sentiment: Recent commentary that LLY may be fully valued, stretched, or expensive has likely added to profit-taking pressure after the stock’s strong advance.
• Negative Sentiment: One market recap noted Eli Lilly fell more than the broader market in the latest session, reflecting a weaker short-term trading tone.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.